Skip to main content

The Clinical Utility and Assessment of Renal Biomarkers in Acute Kidney Injury After Abdominal Endovascular Aneurysm Repair. A Systematic Review.

Publication ,  Journal Article
Karaolanis, G; Williams, ZF; Bakoyiannis, C; Hadjis, D; Cox, MW; Moris, D
Published in: Curr Pharm Des
2019

The widespread adoption of endovascular aneurysm repair (EVAR) for abdominal aortic aneurysms (AAA) is due to the obvious advantages of the procedure compared to the traditional open repair. However, these advantages have to be weighed against the increased risk of renal dysfunction with EVAR. The evaluation of the perioperative renal function after EVAR has been hampered by the lack of sensitive and specific biochemical markers of acute kidney injury (AKI). The purpose of this study was to summarize all novel renal biomarkers and to evaluate their clinical utility for the assessment of the kidney function after EVAR. A systematic review of the current literature, as the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement guidelines, was performed to identify relevant studies with novel renal biomarkers and EVAR. Pubmed and Scopus databases were systemically searched. Studies reporting on thoracic endovascular aortic repair (TEVAR), case reports, case series, letters to the editor, and systematic reviews were excluded. Neutrophil-Gelatinase-Associated Lipocalin, Cystatin C, Liver-type fatty-acid-binding protein were the most common among the eligible studies while Interleukin-18, Retinol binding protein, N-acetyle-b-D-glucosaminidase and microalbumin have a sparse appearance in the literature. These biomarkers have been assessed in plasma as well as urine samples with each sample material having its own advantages and drawbacks. Which of these biomarkers has the most potential for assessing postoperative renal failure after EVAR, remains to be proved. The few studies presented in the literature show the potential clinical utility of these biomarkers, but larger studies with longer follow-up are required to determine the precise relationship between these biomarkers and postoperative acute kidney injury.

Duke Scholars

Published In

Curr Pharm Des

DOI

EISSN

1873-4286

Publication Date

2019

Volume

25

Issue

44

Start / End Page

4695 / 4701

Location

United Arab Emirates

Related Subject Headings

  • Treatment Outcome
  • Risk Factors
  • Retinol-Binding Proteins
  • Postoperative Complications
  • Medicinal & Biomolecular Chemistry
  • Lipocalin-2
  • Interleukin-18
  • Humans
  • Fatty Acid-Binding Proteins
  • Endovascular Procedures
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Karaolanis, G., Williams, Z. F., Bakoyiannis, C., Hadjis, D., Cox, M. W., & Moris, D. (2019). The Clinical Utility and Assessment of Renal Biomarkers in Acute Kidney Injury After Abdominal Endovascular Aneurysm Repair. A Systematic Review. Curr Pharm Des, 25(44), 4695–4701. https://doi.org/10.2174/1381612825666191209122804
Karaolanis, Georgios, Zachary F. Williams, Chris Bakoyiannis, Dimitrios Hadjis, Mitchell W. Cox, and Dimitrios Moris. “The Clinical Utility and Assessment of Renal Biomarkers in Acute Kidney Injury After Abdominal Endovascular Aneurysm Repair. A Systematic Review.Curr Pharm Des 25, no. 44 (2019): 4695–4701. https://doi.org/10.2174/1381612825666191209122804.
Karaolanis G, Williams ZF, Bakoyiannis C, Hadjis D, Cox MW, Moris D. The Clinical Utility and Assessment of Renal Biomarkers in Acute Kidney Injury After Abdominal Endovascular Aneurysm Repair. A Systematic Review. Curr Pharm Des. 2019;25(44):4695–701.
Karaolanis, Georgios, et al. “The Clinical Utility and Assessment of Renal Biomarkers in Acute Kidney Injury After Abdominal Endovascular Aneurysm Repair. A Systematic Review.Curr Pharm Des, vol. 25, no. 44, 2019, pp. 4695–701. Pubmed, doi:10.2174/1381612825666191209122804.
Karaolanis G, Williams ZF, Bakoyiannis C, Hadjis D, Cox MW, Moris D. The Clinical Utility and Assessment of Renal Biomarkers in Acute Kidney Injury After Abdominal Endovascular Aneurysm Repair. A Systematic Review. Curr Pharm Des. 2019;25(44):4695–4701.

Published In

Curr Pharm Des

DOI

EISSN

1873-4286

Publication Date

2019

Volume

25

Issue

44

Start / End Page

4695 / 4701

Location

United Arab Emirates

Related Subject Headings

  • Treatment Outcome
  • Risk Factors
  • Retinol-Binding Proteins
  • Postoperative Complications
  • Medicinal & Biomolecular Chemistry
  • Lipocalin-2
  • Interleukin-18
  • Humans
  • Fatty Acid-Binding Proteins
  • Endovascular Procedures